Dr. Amer Raheemullah, MD, is Clinical Assistant Professor at Stanford University in the Psychiatry and Behavioral Sciences Department. He specializes in the treatment of addiction, has published chapters and peer-reviewed articles in this area, and is Director of the Addiction Medicine Consult Service at Stanford Hospital. He is board-certified in Addiction Medicine and Internal Medicine and has a special interest in developing novel methods to increase access to addiction treatment, through criminal justice, healthcare, and tech-enabled solutions.
He was born and raised in the Chicagoland area. While pursuing his undergraduate degree in Economics at the University of Illinois Urbana-Champaign, he started free education and addiction programs inside Illinois jails and prisons, which continued through his Internal Medicine residency at the University of Illinois College of Medicine. He eventually started Madina House, a non-profit organization focusing on increasing access to addiction treatment for populations over-represented in the criminal justice system.
After completing his Addiction Medicine fellowship at Stanford University School of Medicine, he stayed on the faculty and started the Stanford Hospital Addiction Medicine Consult Service. The service consists of addiction medicine specialists, social workers, substance use navigators, and peer mentors, and by the first year, 30-day readmission rates were reduced by 60% in substance use disorder patients treated by the service, without any increase in length of stay. He also works with the Silicon Valley digital technology startup, Lucid Lane, to put forth a nationwide response to the opioid epidemic, by leveraging data-driven, tech-enabled solutions to scale access to evidence-based treatment.
- Opioid Dependence
- Benzodiazepine Dependence
- Prescription Medication Tapering
- Internal Medicine
- Smoking Cessation
- Addiction Medicine
Clinical Assistant Professor, Psychiatry and Behavioral Sciences
Director, Inpatient Addiction Medicine Consult Service (2018 - Present)
Fellowship: Stanford University Addiction Medicine Fellowship (2018) CA
Board Certification: American Board of Preventive Medicine, Addiction Medicine (2019)
Board Certification, Addiction Medicine, American Board of Preventive Medicine (2019)
Fellowship, Stanford University School of Medicine, Addiction Medicine (2018)
Board Certification: American Board of Internal Medicine, Internal Medicine (2017)
Residency, University of Illinois College of Medicine, Internal Medicine (2017)
Internship, University of Illinois College of Medicine (2014)
Ambulatory Alcohol Detoxification With Remote Monitoring
This study is designed to examine the feasibility and impact of the use of remote monitoring devices during an outpatient ambulatory alcohol detoxification treatment for patients with alcohol use disorders.
A telehealth inpatient addiction consult service is both feasible and effective in reducing readmission rates.
Journal of addictive diseases
The COVID-19 pandemic compelled fast adaptation of telehealth to addiction treatment services. This study aims to examine the feasibility and effectiveness of transitioning an in-person hospital addiction consult service (ACS) to telehealth. The Stanford Hospital ACS adapted to the pandemic by transforming an in-person ACS to a telehealth ACS. We compared 30-day readmission rates in patients with and without an addiction medicine consult pre-pandemic (in-person ACS) and during the pandemic (telehealth ACS). The ACS completed 370 and 473 unique patient consults in the year preceding (in-person consults) and during the pandemic (telehealth consults) respectively. Patients seen by telehealth ACS had decreased 30-day readmission rates consistent with those seen before COVID-19. A telehealth ACS is feasible and effective in the in-patient setting. Telehealth ACS holds promise to extend the reach of substance use disorder evaluation and treatment in underserved areas.
View details for DOI 10.1080/10550887.2022.2090822
View details for PubMedID 35819268
Dopamine Nation: Finding Balance in the Age of Indulgence by Anna Lembke, New York: Dutton, 2021
Cambridge Quarterly of Healthcare Ethics
2022; 31 (4): 573-574
View details for DOI 10.1017/S0963180122000032
- Alcohol and Other Substance Use Disorders Concise Guide to Neuropsychiatry and Behavioral Neurology American Psychiatric Publishing, Inc.. 2022; 3rd: 337-348
- Inpatient Addiction Medicine Consultation on Readmission Rates and Length of Stay Journal of Addiction and Prevention 2022; 10 (1)
Inpatient Motivational Interventions for Substance Use Disorder
J Mod Nurs Pract Res
2022; 2 (4): 11
View details for DOI 10.53964/jmnpr.2022011
Peer Review Report For: Creating a standard inpatient opioid withdrawal protocol.
2022; 12 (7)
View details for DOI 10.21956/mep.18808.r31926
Buprenorphine Induction Without Opioid Withdrawal: A Case Series of 15 Opioid-Dependent Inpatients Induced on Buprenorphine Using Microdoses of Transdermal Buprenorphine
AMERICAN JOURNAL OF THERAPEUTICS
2021; 28 (4): E504-E508
View details for Web of Science ID 000681356600019
Improving Residency Education on Chronic Pain and Opioid Use Disorder: Evaluation of CDC Guideline-Based Education.
Substance use & misuse
Background: National surveys show that primary care physicians feel responsible for addressing the opioid epidemic. They feel their training in managing chronic pain and addiction was insufficient, and commonly endorse the need for more residency training in these areas. However, residency training in these areas remains low, with a lack of faculty expertise and time as the most commonly cited barriers for improvement. Objective: To evaluate the feasibility of an educational program for chronic pain management and addiction that does not rely on faculty expertise or additional time, and assess resident opioid-prescribing practices and confidence in managing chronic pain after its implementation. Methods: A 16-week educational curriculum was incorporated into existing residency didactics. Internal medicine residents attended six educational sessions in 2016 over a 16-week period and implemented a protocol based on CDC Guidelines for Prescribing Opioids for Chronic Pain. Surveys were completed pre- and post-intervention. Results: Implementation of this educational intervention was feasible. Surveys showed improvement in resident confidence in detecting and managing addiction and improved prescribing practices and adherence to CDC recommendations. Conclusion: This pilot study demonstrates that increasing residency education in managing chronic pain and opioid use disorder is feasible, and no longer needs to be postponed due to lack of time or faculty expertise.
View details for DOI 10.1080/10826084.2019.1691600
View details for PubMedID 31757179
Initiating Opioid Agonist Treatment for Opioid Use Disorder in the Inpatient Setting: A Teachable Moment.
JAMA internal medicine
View details for PubMedID 30640372
- Buprenorphine Induction Without Opioid Withdrawal: A Case Series of 15 Opioid-Dependent Inpatients Induced on Buprenorphine Using Microdoses of Transdermal Buprenorphine. American journal of therapeutics 2019
Exercise and Addiction
View details for Web of Science ID 000552225000010
- Cocaine Cessation for Levamisole-Induced Vasculitis: Treating the Underlying Disease. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2019
- Exercise and Addiction Lifestyle Pscyhiatry American Psychiatric Association Publishing. 2019: 127
Fentanyl analogue overdose: Key lessons in management in the synthetic opioid age.
Journal of Opioid Management
2019; 15 (5): 428-432
View details for DOI 10.5055/jom.2019.0531
Eccrine Porocarcinoma Presenting as a Hand Cyst.
journal of hand surgery
2016; 41 (11): e425-e427
Eccrine porocarcinoma is a rare tumor that arises from the epithelium of the eccrine ducts, with a tendency for metastatic spread and a high rate of local recurrence after excision. It was first described in 1963 by Pinkus and Mehregan and can present clinically as a nodule, erosive plaque or a polypoid growth that may ulcerate. The variable clinical appearance of these lesions can make diagnosis challenging and could delay appropriate treatment. If metastasis occurs the prognosis is poor, with a reported mortality rate of up to 80%. We report an uncommon presentation of porocarcinoma as a cyst on the dorsum of the right hand in a 37-year-old man. Only 8% of porocarcinomas occur in the upper extremity and only 3% are on the hand. Furthermore, the tumor is more common in females and mean age at diagnosis is 67 years. Treatment is with wide local excision with free tumor borders confirmed by biopsy, which has been shown to be curative in 70% to 80% of patients.
View details for DOI 10.1016/j.jhsa.2016.07.112
View details for PubMedID 27593487
REPEATED THROMBOSIS AFTER SYNTHETIC CANNABINOID USE
JOURNAL OF EMERGENCY MEDICINE
2016; 51 (5): 540-543
Synthetic cannabinoids are swiftly gaining popularity and have earned a reputation of being relatively safer than other illicit drugs. However, there is a growing body of literature associating thromboembolic events with their use.A 32-year-old woman presented on four separate occasions with a new thromboemoblic event after smoking synthetic cannabinoids. She had no medical history, and over the span of 9 months she developed two kidney infarcts, pulmonary emboli, and an ischemic stroke. Each of these events occurred within 24 hours of smoking synthetic cannabinoids. During periods of abstinence, she remained free of thrombotic events. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: This report shows that an association between thrombosis and the use of synthetic cannabinoids is reproducible and involves both venous and arterial thrombosis, suggesting activation of coagulation or inflammatory pathways. As the popularity of this drug continues to grow, we can expect to see a growing number of these cases. Synthetic cannabinoid use should be included in the differential diagnosis of young patients with no risk factors who present with venous or arterial thrombosis.
View details for Web of Science ID 000389520200012
View details for PubMedID 27595371